Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

NIH to Significantly Reduce the use of Chimpanzees in Research

Published: Friday, June 28, 2013
Last Updated: Friday, June 28, 2013
Bookmark and Share
NIH plans to retain but not breed up to 50 chimpanzees for future biomedical research.

The National Institutes of Health plans to substantially reduce the use of chimpanzees in NIH-funded biomedical research and designate for retirement most of the chimpanzees it currently owns or supports. NIH Director Francis S. Collins, M.D., Ph.D. accepted most of the recommendations made by an independent advisory council for implementing a set of principles and criteria defined by the Institute of Medicine for the use of chimpanzees in NIH-funded research.

The chimpanzees that will remain available for research will be selected based on research projects that meet the IOM’s principles and criteria for NIH funding. The chimpanzees designated for retirement could eventually join more than 150 other chimpanzees already in the Federal Sanctuary System. The Federal Sanctuary System was established in 2002 by the Chimpanzee Health Improvement, Maintenance and Protection (CHIMP) Act   and Chimp Haven operates the Federal Sanctuary System, which is overseen by NIH.

“Americans have benefitted greatly from the chimpanzees’ service to biomedical research, but new scientific methods and technologies have rendered their use in research largely unnecessary,” said Dr. Collins. “Their likeness to humans has made them uniquely valuable for certain types of research, but also demands greater justification for their use. After extensive consideration with the expert guidance of many, I am confident that greatly reducing their use in biomedical research is scientifically sound and the right thing to do.”

In accepting the recommendations, NIH plans to:

• retain but not breed a small fraction of chimpanzees for future research that meets the IOM principles and criteria

• provide ethologically appropriate facilities (i.e., as would occur in their natural environment) for those chimpanzees as defined by NIH based on the advisory council recommendations and with space requirements yet to be determined

• establish a review panel to consider research projects proposing the use of chimpanzees with the IOM principles and criteria after projects have cleared the NIH peer review process

• wind down research projects using NIH-owned or -supported chimpanzees that do not meet the IOM principles and criteria in a way that preserves the research and minimizes the impact on the animals

• retire the majority of the NIH-owned chimpanzees deemed unnecessary for biomedical research to the Federal Sanctuary System contingent upon resources and space availability in the sanctuary system

Some technical changes in NIH’s legal authority are needed to retire additional chimpanzees to the Federal Sanctuary System. NIH will continue working with Congress to remedy a provision that currently limits the amount of financial resources NIH may put toward retiring chimpanzees and caring for them in the Federal Sanctuary System.

While broadly accepting the recommendations of ethologically appropriate facilities, NIH did not accept, due to the lack of scientific consensus, the recommendation that the primary living space of research chimpanzees be at least 1,000 square feet per chimpanzee. NIH will engage chimpanzee behavior and facilities experts to determine the appropriate minimum space requirement for research chimpanzees.

“Today’s decision by NIH culminates more than two years of intensive deliberations among NIH leadership, independent chimpanzee experts, researchers, bioethicists, and members of the public,” said James M. Anderson, M.D., Ph.D., NIH deputy director for program coordination, planning, and strategic initiatives, whose division oversees the NIH Chimpanzee Management Program. “We are grateful to all who have contributed their insight and expertise during the advisory process.”

NIH’s full response to the recommendations and public comments can be found here

The events that led to the decision by NIH are:

• In December 2010, the NIH Director commissioned a study by the Institute of Medicine to determine the continued scientific need for chimpanzees in NIH-funded research  .

• The IOM, in its recommendations in December 2011, concluded that most current use of chimpanzees in biomedical research is unnecessary and that the use of chimpanzees in research that may still be needed should be guided by a set of principles and criteria.

• That same month, Dr. Collins accepted the IOM recommendations. He charged a working group of the Council of Councils (CoC), an independent advisory committee, to make recommendations on how NIH should implement the IOM principles and criteria.

• The CoC presented its recommendations(PDF - 695KB) in January 2013.

• The CoC recommendations were issued for public comment in the same month.

The U.S. Fish and Wildlife Service (USFWS) recently issued a proposed rule (PDF - 695KB)   that lists captive chimpanzees as endangered. NIH expects to adapt its policies for research projects using chimpanzees to comply with the conservation guidelines that the USFWS establishes in a potential final rule.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Wednesday, September 30, 2015
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Tuesday, September 29, 2015
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Friday, June 26, 2015
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Monday, November 10, 2014
NIH Launches 3 Integrated Precision Medicine Trials
Findings to answer questions about addition of targeted therapies in earlier stage disease and help understand the prevalence and natural history of these genomic changes in earlier stage lung cancer.
Wednesday, August 20, 2014
Study Finds Gut Microorganisms May Determine Cancer Treatment Outcome
An intact population of microorganisms that derive food and benefit from other organisms living in the intestine is required for optimal response to cancer therapy.
Monday, November 25, 2013
NIH Scientists Pursue New Therapies to Improve Rare Disease Drug Development
Projects selected for potential to treat specific rare diseases.
Friday, September 13, 2013
Improving Gene Therapy for Eye Diseases
Researchers developed a less invasive technique that delivers genes across the retinas of mouse and monkey eyes.
Friday, July 05, 2013
NIH Funds Development of Tissue Chips to Help Predict Drug Safety
DARPA and FDA to collaborate on therapeutic development initiative.
Wednesday, July 25, 2012
Blockade of Learning and Memory Genes may Occur Early in Alzheimer's Disease
A repression of gene activity in the brain appears to be an early event affecting people with Alzheimer's disease. In mouse models of Alzheimer's disease, this epigenetic blockade and its effects on memory were treatable.
Thursday, March 01, 2012
Researchers to Pioneer Advanced Biomolecule Discovery Technology
The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.
Monday, November 28, 2011
NIH, DARPA and FDA Collaborate to Develop Cutting-Edge Technologies to Predict Drug Safety
The collaboration will develop a chip to screen for safe and effective drugs far more swiftly and efficiently than current methods, and before they are tested in humans.
Monday, September 19, 2011
NIH-Funded Study Shows Early Brain Effects of HIV in Mouse Model
A new mouse model closely resembles how the human body reacts to early HIV infection and is shedding light on nerve cell damage related to the disease.
Thursday, March 03, 2011
Drug-Like Compound Stops Thyroid Overstimulation in Early NIH Studies
Researchers at the National Institutes of Health have identified a compound that prevents overproduction of thyroid hormone, a finding that brings scientists one step closer to improving treatment for Graves' disease.
Thursday, December 02, 2010
Clinical Tests Begin on Medication to Correct Fragile X Defect
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability.
Monday, November 02, 2009
Scientific News
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Combo of 3 Antibiotics Can Kill Deadly Staph Infections
Three antibiotics that, individually, are not effective against a drug-resistant staph infection can kill the deadly pathogen when combined as a trio, according to new research.
Microbe Artwork Shows The Limits Of Antibiotics
An Oxford University research fellow has been creating art using bacteria found in the human gut and harvested from faecal samples.
Urine Excretion From Stem Cell-Derived Kidneys
Researchers report a strategy for enabling urine excretion from kidneys grown from stem cells.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos